Zymeworks is a clinical-stage biopharmaceutical company focused on the development of multifunctional biotherapeutics. Co.'s primary product candidate, zanidatamab, is a bispecific (dual-targeting) antibody that targets two domains of the human epidermal growth factor receptor 2. Co.'s second product candidate, ZW49, combines the design of zanidatamab with its ZymeLink antibody-drug conjugate platform, comprised of its proprietary cytotoxin (cancer cell-killing compound) and cleavable linker. Co. is also developing a pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeutic areas. The ZYME average annual return since 2017 is shown above.
The Average Annual Return on the ZYME average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ZYME average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ZYME average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|